Table 1.
Dichotomous clinical and nerve conduction measures used to identify distal symmetrical neuropathy at DCCT baseline and at DCCT completion
| DCCT baseline | DCCT completion | ||||
|---|---|---|---|---|---|
| All subjects | Subgroup 1 | Subgroup 2 | Subgroup 3 | Subgroup 4* | |
| Attribute/nerve (n) | |||||
| Intensive treatment group | 711 | 647 | 607 | 470 | 361 |
| Conventional treatment group | 730 | 606 | 567 | 330 | 228 |
| Clinical evidence of distal symmetrical neuropathy | |||||
| Symptoms | |||||
| Intensive treatment group | 5.8 | 4.2 | 2.4† | 2.7† | 0.3 |
| Conventional treatment group | 6.6 | 7.5 | 5.5 | 7.1 | 1.4 |
| Sensory signs | |||||
| Intensive treatment group | 22.1 | 18.3 | 13.6 | 12.6 | 0.3 |
| Conventional treatment group | 20.8 | 21.6 | 16.2 | 14.9 | 1.0 |
| Decreased reflexes | |||||
| Intensive treatment group | 18.0 | 17.8‡ | 13.7‡ | 11.1 | 1.2 |
| Conventional treatment group | 15.7 | 25.9 | 21.7 | 15.2 | 3.4 |
| Nerve conduction abnormality of selected nerve | |||||
| Abnormal median motor | |||||
| Intensive treatment group | 20.9 | 11.4§ | 11.3§ | 4.2 | 3.8 |
| Conventional treatment group | 22.8 | 24.5 | 25.3 | 7.4 | 7.6 |
| Abnormal median sensory | |||||
| Intensive treatment group | 34.1 | 39.0 | 39.8 | 27.0 | 25.1 |
| Conventional treatment group | 32.0 | 42.9 | 44.3 | 24.0 | 23.3 |
| Abnormal peroneal motor | |||||
| Intensive treatment group | 35.4† | 23.8§ | 24.4§ | 11.2‡ | 11.2 |
| Conventional treatment group | 42.3 | 46.1 | 47.9 | 19.9 | 17.1 |
| Abnormal sural sensory | |||||
| Intensive treatment group | 28.5 | 21.4§ | 22.2‡ | 7.4 | 6.5 |
| Conventional treatment group | 26.1 | 31.3 | 32.4 | 6.4 | 5.7 |
Data are percent, unless otherwise indicated. The dichotomous clinical and nerve conduction results for DCCT completion reflect analyses after sequentially excluding subjects with confirmed clinical neuropathy, the primary DCCT neuropathy end point (subgroup 1); definite clinical neuropathy (subgroup 2); definite clinical neuropathy or possible clinical neuropathy (subgroup 3); and definite clinical neuropathy, possible clinical neuropathy, or subclinicalneuropathy (subgroup 4). Subgroup 4 represents subjects who did not meet any of the DCCT definitions of clinical or subclinical neuropathy.
The prevalence of symptoms and signs in this subgroup is not zero because the neurologist concluded that the potential abnormality consistent with distal symmetrical neuropathy had another explanation (e.g., 11 subjects had diffusely hypoactive or absent reflexes without symptoms or other signs of neuropathy).
P < 0.01;
P < 0.001;
P < 0.0001.